Wire · opportunities
Telehealth Platform Expands Access to FDA-Approved Obesity Medications
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 November 2026 · Fusion42 review
Hims & Hers has partnered with Eli Lilly to offer FDA-approved obesity medications through its telehealth platform, allowing eligible patients to access prescribed treatments at self-pay prices starting from $149 per month, combined with clinical consultations and virtual care support.
This Wire brief sits within Fusion42's coverage of Digital Health, and 6 sources have reported it between 6 Nov 2026 and 14 Nov 2026.
◆ ◆ The Wire takeaway
You can now offer obesity treatments directly to patients remotely without payor delays or in-person visits. This opens a direct care channel and reshapes how you price and deliver prescription weight loss solutions.
◆ Coverage
6 sources · first reported 6 Nov 2026 · latest 14 Nov 2026
◆ Related on Wire
◆ Topics